Evidence Hub

AGA living clinical practice guideline on the pharmacologic management of moderate-to-severe crohn’s disease

Frank I. Scott, Ashwin Ananthakrishnan, Ben Click, Manasi Agrawal, Gaurav Syal, John P Haydek, Yu-Hong Yuan, M. Kappelman et al.

Gastroenterology, 2025

29 citations

Abstract

Background & Aims: This American Gastroenterological Association (AGA) living guideline is intended to support practitioners in the pharmacological management of moderate-to-severe Crohn’s Disease (CD). Methods: A multi-disciplinary panel of clinical experts and methodologists utilized the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework to prioritize clinical questions, identify patient-centered outcomes, conduct an evidence synthesis, and develop recommendations. Results: The Guideline Panel agreed on 16 recommendations, of which one is a strong recommendation, nine are conditional recommendations and six were identified as knowledge gaps. In adult patients with moderate-to-severely active CD, the AGA recommends the use of infliximab, adalimumab, ustekinumab, risankizumab, mirikizumab, guselkumab and upadacitinib over no treatment, and suggests the use of certolizumab pegol and vedolizumab over no treatment. In individuals who are naïve to advanced therapies, the AGA suggests using a higher efficacy medication (infliximab, adalimumab, vedolizumab, ustekinumab, risankizumab, mirikizumab, or guselkumab) rather than a lower efficacy medication (certolizumab pegol, upadacitinib). In individuals who have previously been exposed to one or more advanced therapies, the AGA suggests using a higher efficacy medication (adalimumab, risankizumab, guselkumab, upadacitinib) or intermediate efficacy medication (ustekinumab, mirikizumab) rather than a…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free